The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Applications include detailed scientific rationale and supporting clinical evidence
Expands bioprocessing footprint across Asia
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The new site enables end-to-end production of viral vector gene therapies
Merck opens first climate-neutral manufacturing facility in Ireland
Subscribe To Our Newsletter & Stay Updated
